| Previous close | 5,113.00 |
| Open | 4,346.00 |
| Bid | 4,300.00 x 6100 |
| Ask | 4,398.00 x 13000 |
| Day's range | 4,260.00 - 4,399.00 |
| 52-week range | 3,996.00 - 5,520.00 |
| Volume | 10,636,810 |
| Avg. volume | 1,964,254 |
| Market cap | 54.74B |
| Beta | 0.67 |
| PE ratio (TTM) | 16.20 |
| EPS (TTM) | 267 |
| Earnings date | 27 Jul 2017 |
| Dividend & yield | 2.80 (4.25%) |
| Ex-dividend date | 2017-02-16 |
| 1y target est | 68.85 |
- Motley Fool•18 minutes ago
Why Twitter, AstraZeneca, and Spirit Airlines Slumped Today
These stocks helped pull the market down. Find out why.
- Investor's Business Daily•33 minutes ago
How AstraZeneca Failed Not Once — But Twice — In Cancer Drugs
AstraZeneca not only failed in a lung cancer trial but its partnership with Dow's Merck appears to be an admission of defeat.
- TheStreet.com•38 minutes ago
With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too
The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.
